Year: 2018
Type: review
Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.
Source: Oncogene
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,990
Awards: Investigations of Consequences of U2AF1 Mutations in MDS, G2902946885, G4005777181, G424740486, G4262725454, G4355877210, Therapeutic Implications of Molecular Defects in Bone Marrow Failure, Novel Spliceosomal Defects in Myelodysplastic Syndromes, RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target, UNC Oncology K12
OpenAlex ID: W2793046629
